Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice

Neuropharmacology

Volumn 70, Issue , 2013, Pages 218-227

  Halberstadt, Adam L ^a   Powell, Susan B ^a,b   Geyer, Mark A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

5 HT2A receptor; Hallucinogen; Hyperactivity; Investigatory behavior; Locomotor activity; Mescaline; Rearing

Indexed keywords

2,4,5 TRIMETHOXYAMPHETAMINE; 2,5 DIMETHOXY 4 PROPYLAMPHETAMINE; 2,5 DIMETHOXY 4 TERT BUTYLAMPHETAMINE; 4 ETHYL 2,5 DIMETHOXYAMPHETAMINE; AMPHETAMINE DERIVATIVE; MESCALINE; PHENETHYLAMINE; PHENYLALKYLAMINE; PSYCHEDELIC AGENT; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; VOLINANSERIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONFORMATION; CONTROLLED STUDY; EXPERIMENTAL DESIGN; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANILINE COMPOUNDS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUOROBENZENES; HALLUCINOGENS; HYPERKINESIS; MALE; MICE; MICE, KNOCKOUT; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84876987112     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.01.014     Document Type: Article

References (53)

1. H.M. Abdolmaleky, S. Yaqubi, P. Papageorgis, A.W. Lambert, S. Ozturk, V. Sivaraman, and S. Thiagalingam Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder Schizophr. Res. 129 2011 183 190
2. L. Adams, and M.A. Geyer Effects of DOM and DMT in a proposed animal model of hallucinogenic activity Prog. Neuropsychopharmacol. Biol. Psychiatry 9 1985 121 132
3. K.A. Berg, S. Maayani, J. Goldfarb, C. Scaramellini, P. Leff, and W.P. Clarke Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus Mol. Pharmacol. 54 1998 94 104
4. B.R. Brookshire, and S.R. Jones Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL/6J mice Pharmacol. Biochem. Behav. 94 2009 194 203
5. O.L. Carter, D.C. Burr, J.D. Pettigrew, G.M. Wallis, F. Hasler, and F.X. Vollenweider Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors J. Cogn. Neurosci. 17 2005 1497 1508
6. O.L. Carter, F. Hasler, J.D. Pettigrew, G.M. Wallis, G.B. Liu, and F.X. Vollenweider Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans Psychopharmacology 195 2007 415 424
7. S.F. Chen, Y.C. Shen, and C.H. Chen HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients Psychopharmacology 205 2009 285 292
8. N.A. Darmani, B.R. Martin, U. Pandey, and R.A. Glennon Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol. Biochem. Behav. 36 1990 901 906
9. N.A. Darmani, J. Shaddy, and C.F. Gerdes Differential ontogenesis of three DOI-induced behaviors in mice Physiol. Behav. 60 1996 1495 1500
10. W.E. Fantegrossi, J. Simoneau, M.S. Cohen, S.M. Zimmerman, C.M. Henson, K.C. Rice, and J.H. Woods Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice J. Pharmacol. Exp. Ther. 335 2010 728 734
11. 2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis Psychopharmacology 121 1995 347 356
12. 2A receptor agonist TCB-2: a behavioral and neurophysiological analysis Psychopharmacology 212 2009 13 23
13. R.A. Glennon, J.A. Rosecrans, and R. Young Drug-induced discrimination: a description of the paradigm and a review of its application in the study of hallucinogenic agents Med. Res. Rev. 3 1983 289 340
14. 2 involvement in the mechanisms of action of hallucinogenic agents Life Sci. 35 1984 2505 2511
15. R.A. Glennon, M. Titeler, and E. Sanders-Bush Hallucinogens and serotonergic mechanisms NIDA Res. Monogr. 119 1992 131 135
16. R.A. Glennon, R. Young, and J.A. Rosecrans A comparison of the behavioral effects of DOM homologs Pharmacol. Biochem. Behav. 16 1982 557 559
17. 2A receptor-mediated signaling pathways to affect behavior Neuron 53 2007 439 452
18. A.L. Halberstadt, and M.A. Geyer Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens Neuropharmacology 61 2011 364 381
19. A.L. Halberstadt, L. Koedood, S.B. Powell, and M.A. Geyer Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice J. Psychopharmacol. 25 2011 1548 1561
20. 2A receptors on locomotor activity in mice Psychopharmacology 215 2011 81 92
21. A.L. Halberstadt, and D.E. Nichols Serotonin and serotonin receptors in hallucinogen action C. Muller, B. Jacobs, Handbook of the Behavioral Neurobiology of Serotonin 2010 Academic London 621 636
22. 2C receptors exert opposing effects on locomotor activity in mice Neuropsychopharmacology 34 2009 1958 1967
23. J. Hannon, and D. Hoyer Molecular biology of 5-HT receptors Behav. Brain Res. 195 2008 198 213
24. T. Kishi, R. Yoshimura, T. Kitajima, T. Okochi, T. Okumura, T. Tsunoka, Y. Yamanouchi, Y. Kinoshita, K. Kawashima, H. Naitoh, J. Nakamura, N. Ozaki, and N. Iwata HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort Neuromolecular. Med. 12 2010 237 242
25. 2C receptors Neuropsychopharmacology 18 1998 339 351
26. A.S. Kulkarni Scratching response induced in mice by mescaline and related amphetamine derivatives Biol. Psychiatry 6 1973 177 180
27. D.M. Kurrasch-Orbaugh, V.J. Watts, E.L. Barker, and D.E. Nichols Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves J. Pharmacol. Exp. Ther. 304 2003 229 237
28. T.H. McLean, J.J. Chambers, J.C. Parrish, M.R. Braden, D. Marona-Lewicka, D. Kurrasch-Orbaugh, and D.E. Nichols C-(4,5,6-trimethoxyindan-1-yl) methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor J. Med. Chem. 49 2006 4269 4274
29. T.H. McLean, J.C. Parrish, M.R. Braden, D. Marona-Lewicka, A. Gallardo-Godoy, and D.E. Nichols 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists J. Med. Chem. 49 2006 5794 5803
30. A.P. Monte, S.R. Waldman, D. Marona-Lewicka, D.B. Wainscott, D.L. Nelson, E. Sanders-Bush, and D.E. Nichols Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives J. Med. Chem. 40 1997 2997 3008
31. P.R. Moya, K.A. Berg, Gutierraz-Hernandez, P. Saez-Briones, M. Reyes-Parada, B.K. Cassels, and W.P. Clarke Functional selectivity of hallucinogenic phenethylamines and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors J. Pharmacol. Exp. Ther. 321 2007 1054 1061
32. R.D. Morin, F. Benington, S.R. Mitchell, J.M. Beaton, R.J. Bradley, and J.R. Smythies The behavioral effects of 2,5-dimethoxy-4-alkyl amphetamines Experentia 31 1975 93 95
33. D.E. Nichols Hallucinogens Pharmacol. Ther. 101 2004 131 181
34. B.B. Quednow, M.A. Geyer, and A.L. Halberstadt Serotonin and schizophrenia C.P. Muller, B. Jacobs, Handbook of the Behavioral Neurobiology of Serotonin 2010 Academic Press London 585 620
35. H. Rasmussen, B.H. Ebdrup, D. Erritzoe, B. Aggernaes, B. Oranje, J. Kalbitzer, L.H. Pinborg, W.F. Baaré, C. Svarer, H. Lublin, G.M. Knudsen, and B. Glenthoj Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine Psychopharmacology 213 2011 583 592
36. V.B. Risbrough, V.L. Masten, S. Caldwell, M.P. Paulus, M.J. Low, and M.A. Geyer Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice Neuropsychopharmacology 31 2006 2349 2358
37. 2 receptor: implications for treating LSD-induced hallucinogenesis Psychopharmacology 98 1989 495 499
38. P.A. Saiz, M.P. García-Portilla, C. Arango, B. Morales, S. Martínez-Barrondo, C. Alvarez, G. San Narciso, E. Carreño, V. Alvarez, E. Coto, and J. Bobes Association between heroin dependence and 5-HT2A receptor gene polymorphisms Eur. Addict. Res. 14 2008 47 52
39. P.A. Saiz, M.P. García-Portilla, B. Paredes, C. Arango, B. Morales, V. Alvarez, E. Coto, M.T. Bascaran, M. Bousoño, and J. Bobes Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts Psychiatr. Genet. 18 2008 213 218
40. 1A agonists J. Pharmacol. Exp. Ther. 273 1995 101 112
41. M.R. Seggel, M.Y. Yousif, R.A. Lyon, M. Titeler, B.L. Roth, E.A. Suba, and R.A. Glennon A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors J. Med. Chem. 33 1990 1032 1036
42. M. Shannon, G. Battaglia, R.A. Glennon, and M. Titeler 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2- aminopropane (2,5-DMA) Eur. J. Pharmacol. 102 1984 23 29
43. A.T. Shulgin, and D.C. Dyer Psychotomimetic phenylisopropylamines. 5. 4-Alkyl-2,5-dimethoxyphenylisopropylamines J. Med. Chem. 18 1975 1201 1204
44. A. Shulgin, and A. Shulgin PIHKAL: a Chemical Love Story 1991 Transform Press Berkeley, CA
45. R.L. Smith, R.J. Barrett, and E. Sanders-Bush Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice Psychopharmacology (Berl) 166 2003 61 68
46. 2 receptor as a site of action for LSD and phenylisopropyl amine hallucinogens Psychopharmacology 94 1988 213 216
47. M. Viikki, K. Huuhka, E. Leinonen, A. Illi, E. Setälä-Soikkeli, M. Huuhka, N. Mononen, T. Lehtimäki, and O. Kampman Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD Neurosci. Lett. 501 2011 20 24
48. F.X. Vollenweider, M.F.I. Vollenweider-Scherpenhuyzen, A. Bäbler, H. Vogel, and D. Hell Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action NeuroReport 9 1998 3897 3902
49. M.J. Wilkie, G. Smith, R.K. Day, K. Matthews, D. Smith, D. Blackwood, I.C. Reid, and C.R. Wolf Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy Pharmacogenomics J. 9 2009 61 70
50. L.L. Wing, G.S. Tapson, and M.A. Geyer 5HT-2 mediation of acute behavioral effects of hallucinogens in rats Psychopharmacology 100 1990 417 425
51. J.C. Winter, A.K. Kieres, M.D. Zimmerman, C.J. Reissig, J.R. Eckler, T. Ullrich, K.C. Rice, R.A. Rabin, and J.B. Richards The stimulus properties of LSD in C57BL/6 mice Pharmacol. Biochem. Behav. 81 2005 830 837
52. T. Yamamoto, and S. Ueki Behavioral effects of 2,5-dimethoxy-4- methylamphetamine (DOM) in rats and mice Eur. J. Pharmacol. 32 1975 156 162
53. H.K. Yoon, J.C. Yang, H.J. Lee, and Y.K. Kim The association between serotonin-related gene polymorphisms and panic disorder J. Anxiety Disord. 22 2008 1529 1534